Sfoglia per Autore
From biology to clinical experience : evolution in the knowledge of neuroendocrine tumours
2009-01-01 E. Bajetta, G. Procopio, S. Pusceddu, F. Pietrantonio, M. Milione, M. Maccauro, E. Verzoni, V. Guadalupi, M. Platania
Succinate dehydrogenase B subunit immunohistochemical expression predicts aggressiveness in well differentiated neuroendocrine tumors of the ileum
2012-08-16 M. Milione, S. Pusceddu, P. Gasparini, F. Melotti, P. Maisonneuve, V. Mazzaferro, F.G. de Braud, G. Pelosi
Pancreatic well-differentiated neuroendocrine neoplasms (PWDNENS) : What place for everolimus and sunitinib derived from esmo clinical practice guidelines in the therapeutic algorithm?
2013-05-01 S. Pusceddu, R. Buzzoni, F. De Braud
Malignant pheochromocytoma and paraganglioma : future considerations for therapy
2013-06-01 R. Buzzoni, S. Pusceddu, A. Damato, E. Meroni, C. Aktolun, M. Milione, V. Mazzaferro, F. De Braud, C. Spreafico, M. Maccauro, N. Zaffaroni, M.R. Castellani
Well-differentiated neuroendocrine tumor of tailgut cyst : A rare entity with controversial medical opportunities
2013-07-01 A. Damato, S. Pusceddu, M. Milione, V. Mazzaferro, M. Magli, E. Seregni, F. De Braud, R. Buzzoni
Safety profile and treatment response of everolimus in different solid tumors : an observational study
2014-01-01 E. Verzoni, S. Pusceddu, R. Buzzoni, E. Garanzini, A. Damato, P. Biondani, I. Testa, P. Grassi, E. Bajetta, F. Debraud, G. Procopio
Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors
2014-01-01 S. Pusceddu, F. De Braud, L. Concas, C. Bregant, L. Leuzzi, B. Formisano, R. Buzzoni
Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy : a phase II ITMO study
2014-08-01 R. Buzzoni, S. Pusceddu, E. Bajetta, F. De Braud, M. Platania, C. Iannacone, M. Cantore, A. Mambrini, A. Bertolini, O. Alabiso, A. Ciarlo, C. Turco, V. Mazzaferro
Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer
2015-03-01 M. Platania, B. Valeri, A. Marchianò, G. Calareso, F. Agustoni, E. Haspinger, S. Pusceddu, M.C. Garassino, F. Gelsomino, F. de Braud
Erratum: Real-world study of everolimus in advanced progressive neuroendocrine tumors (The Oncologist, (2014) 19, (966-974), 10.1634/theoncologist.2014-0037)
2015-05-01 F. Panzuto, M. Rinzivillo, N. Fazio, F. de Braud, G. Luppi, M.C. Zatelli, F. Lugli, P. Tomassetti, F. Riccardi, C. Nuzzo, M.P. Brizzi, A. Faggiano, A. Zaniboni, E. Nobili, D. Pastorelli, S. Cascinu, M. Merlano, S. Chiara, L. Antonuzzo, C. Funaioli, F. Spada, S. Pusceddu, A. Fontana, M.R. Ambrosio, A. Cassano, D. Campana, G. Cartenì, M. Appetecchia, A. Berruti, A. Colao, M. Falconi, G. Delle Fave
Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options : a systematic review
2015-07-01 S. Pusceddu, F. De Braud, F. Festinese, C. Bregant, A. Lorenzoni, M. Maccauro, M. Milione, L. Concas, B. Formisano, L. Leuzzi, V. Mazzaferro, R. Buzzoni
Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors
2016-01-01 G. Lo Russo, S. Pusceddu, N. Prinzi, M. Imbimbo, C. Proto, D. Signorelli, M. Vitali, M. Ganzinelli, M. Maccauro, R. Buzzoni, E. Seregni, F. de Braud, M.C. Garassino
Diagnosis and management of typical and atypical lung carcinoids
2016-04-01 S. Pusceddu, G. Lo Russo, M. Macerelli, C. Proto, M. Vitali, D. Signorelli, M. Ganzinelli, P. Scanagatta, L. Duranti, A. Trama, R. Buzzoni, G. Pelosi, U. Pastorino, F. de Braud, M.C. Garassino
How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies
2016-04-01 S. Pusceddu, F. De Braud, G. Lo Russo, L. Concas, D. Femia, C. Vernieri, A. Indini, B. Formisano, R. Buzzoni
Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes
2016-05-01 S. Pusceddu, R. Buzzoni, C. Vernieri, L. Concas, S. Marceglia, L. Giacomelli, M. Milione, L. Leuzzi, D. Femia, B. Formisano, V. Mazzaferro, F. De Braud
Treatment of lung large cell neuroendocrine carcinoma
2016-06-01 G. Lo Russo, S. Pusceddu, C. Proto, M. Macerelli, D. Signorelli, M. Vitali, M. Ganzinelli, R. Gallucci, N. Zilembo, M. Platania, R. Buzzoni, F. de Braud, M.C. Garassino
Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up
2016-08-01 C. Vernieri, D. Femia, S. Pusceddu, C. Capella, J. Rosai, G. Calareso, L. Concas, N. Prinzi, G. Lo Russo, F. De Braud, R. Buzzoni
Update on medical treatment of small intestinal neuroendocrine tumors
2016-09-01 S. Pusceddu, D. Femia, G. Lo Russo, S. Ortolani, M. Milione, M. Maccauro, C. Vernieri, N. Prinzi, L. Concas, L. Leuzzi, F. De Braud, R. Buzzoni
Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver
2017-01-01 D. Citterio, S. Pusceddu, A. Facciorusso, J. Coppa, M. Milione, R. Buzzoni, M. Bongini, F. Debraud, V. Mazzaferro
The underestimated role of somatostatin analogs in the NETTER-1 trial
2017-06-01 S. Pusceddu, R. Buzzoni, F. De Braud
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile